氨甲环酸给药与创伤后静脉血栓栓塞风险增加相关
该回顾性研究查询了2012至2016年一家一级创伤中心收治的创伤患者,采用倾向匹配混合效应多因素logistic回归分析氨甲环酸与静脉血栓栓塞的关联。在21,931例患者中匹配出189对,氨甲环酸组静脉血栓栓塞的调整比值比为3.3(95%CI 1.3-9.1,p=0.02),生存无显著差异(aOR 0.86,95%CI 0.23-3.25,p=0.83)。考虑死亡竞争风险后,氨甲环酸组静脉血栓栓塞风险仍升高(亚分布风险比2.42,95%CI 1.11-5.29,p=0.03)。作者认为氨甲环酸可能是静脉血栓栓塞的独立危险因素,未来需研究哪些患者获益最大以个体化治疗。
要点
- 创伤患者使用氨甲环酸与静脉血栓栓塞风险增加三倍以上相关(aOR 3.3,95%CI 1.3-9.1,p=0.02)。
- 氨甲环酸与生存无显著关联(aOR 0.86,95%CI 0.23-3.25,p=0.83)。
- 考虑死亡竞争风险后,氨甲环酸组静脉血栓栓塞风险仍升高(亚分布风险比2.42,95%CI 1.11-5.29,p=0.03)。
- 匹配后氨甲环酸组与非氨甲环酸组中位损伤严重度评分分别为19(四分位距12-27)和14(四分位距8-22),p=0.19。
- 作者认为氨甲环酸可能是静脉血栓栓塞的独立危险因素,未来需识别最可能获益的患者以个体化治疗。
适用人群与场景
- 2012至2016年就诊于一家一级创伤中心的创伤患者。
研究设计与关键结果
- 回顾性研究,查询一家一级创伤中心2012至2016年创伤患者,共21,931例,倾向匹配后189对匹配良好(标准化差异<0.2)。
- 主要结局为肺栓塞或深静脉血栓的复合终点,氨甲环酸与静脉血栓栓塞风险增加相关(aOR 3.3,95%CI 1.3-9.1,p=0.02)。
- 氨甲环酸与生存无显著关联(aOR 0.86,95%CI 0.23-3.25,p=0.83)。
- 考虑死亡竞争风险后,氨甲环酸组静脉血栓栓塞风险仍升高(亚分布风险比2.42,95%CI 1.11-5.29,p=0.03)。
- 匹配后氨甲环酸组中位损伤严重度评分为19(四分位距12-27),非氨甲环酸组为14(四分位距8-22),p=0.19。
证据类型、等级与局限
- 证据类型:回顾性研究;证据等级:治疗性,III级。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为氨甲环酸可能是静脉血栓栓塞的独立危险因素,未来需研究哪些患者从氨甲环酸获益最大,尤其考虑到该干预的风险,以实现个体化治疗、最大化获益并减轻潜在伤害。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Tranexamic acid (TXA) is used as a hemostatic adjunct for hemorrhage control in the injured patient and reduces early preventable death. However, the risk of venous thromboembolism (VTE) has been incompletely explored. Previous studies investigating the effect of TXA on VTE vary in their findings. We performed a propensity matched analysis to investigate the association between TXA and VTE following trauma, hypothesizing that TXA is an independent risk factor for VTE.
METHODS: This retrospective study queried trauma patients presenting to a single Level I trauma center from 2012 to 2016. Our primary outcome was composite pulmonary embolism or deep vein thrombosis. Mortality, transfusion, intensive care unit and hospital lengths of stay were secondary outcomes. Propensity matched mixed effects multivariate logistic regression was used to determine adjusted odds ratio (aOR) and 95% confidence intervals (95% CI) of TXA on outcomes of interest, adjusting for prespecified confounders. Competing risks regression assessed subdistribution hazard ratio of VTE after accounting for mortality.
RESULTS: Of 21,931 patients, 189 pairs were well matched across propensity score variables (standardized differences <0.2). Median Injury Severity Score was 19 (interquartile range, 12-27) and 14 (interquartile range, 8-22) in TXA and non-TXA groups, respectively (p = 0.19). Tranexamic acid was associated with more than threefold increase in the odds of VTE (aOR, 3.3; 95% CI, 1.3-9.1; p = 0.02). Tranexamic acid was not significantly associated with survival (aOR, 0.86; 95% CI, 0.23-3.25; p = 0.83). Risk of VTE remained elevated in the TXA cohort despite accounting for mortality (subdistribution hazard ratio, 2.42; 95% CI, 1.11-5.29; p = 0.03).
CONCLUSION: Tranexamic acid may be an independent risk factor for VTE. Future investigation is needed to identify which patients benefit most from TXA, especially given the risks of this intervention to allow a more individualized treatment approach that maximizes benefits and mitigates potential harms.
LEVEL OF EVIDENCE: Therapeutic, level III.
参考来源
- Myers SP, Kutcher ME, Rosengart MR, et al. Tranexamic acid administration is associated with an increased risk of posttraumatic venous thromboembolism. J Trauma Acute Care Surg. 2019. PMID: 30239375. doi:10.1097/TA.0000000000002061
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。